Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

European Journal of Clinical Pharmacology

Volumn 68, Issue 6, 2012, Pages 987-995

  Vehreschild, J J ^a   Muller C ^a   Farowski, F ^a   Vehreschild, M J G T ^a   Cornely, O A ^a,b,c   Fuhr, U ^a   Kreuzer, K A ^a   Hallek, M ^a   Kohl, V ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Aspergillosis; Chemotherapy; Drug drug interactions; NONMEM; Posaconazole; Therapeutic drug monitoring

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; PANTOPRAZOLE; POSACONAZOLE; RANITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; COHORT STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOSES; MYELODYSPLASTIC SYNDROMES; SUSPENSIONS; TRIAZOLES; YOUNG ADULT;

EID: 84864286296     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1212-y     Document Type: Article

References (33)

1. Lass-Florl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52(3):197-205
2. Vehreschild JJ, Rüping MJGT, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer K-A, Hallek M, Bangard C, Cornely OA (2010) Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukemia (AML): A six year experience of the Cologne AML Cohort. J Antimicrob Chemother 65:1466-1471
3. Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ, Castelli MV, Gomez-Lopez A, Zaragoza O, Rodriguez-Tudela JL (2008) Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents 32[Suppl 2]:S143-S147. doi:10.1016/S0924-8579 (08)70016-5
4. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356(24):2472-2482. doi:10.1056/NEJMoa066906 (Pubitemid 46919773)
5. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (6):408-415 (Pubitemid 34851833)
6. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335-347 (Pubitemid 46148776)
7. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348-359. doi:10.1056/NEJMoa061094 (Pubitemid 46148777)
8. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327-360. doi:10.1086/ 525258 (Pubitemid 351265310)
9. European LeukemiaNet, European Group for Blood & Marrow Transplantation, European Organization for Research and Treatment of Cancer and International Immunocompromised Host Society (2007). 2007 Update of the ECIL-1 guidelines for antifungal prophylaxis in leukemia patients, including allogeneic HSCT recipients. Available at: http://www.ichs.org/Ecilslides/ ECIL2%20%20Antifungal%20prophylaxis%20update%202007.pdf. Accessed 9 Mar 2010
10. Cornely OA, Bohme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Kruger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the infectious diseases working party of the German society for haematology and oncology. Haematologica 94 (1):113-122. doi:10.3324/ haematol.11665
11. National Comprehensive Cancer Network (2009) National Comprehensive Cancer Network clinical practice guidelines in oncology: prevention and treatment of cancer-related Infections v.2.2009. Available at: http://www.nccn.org/professionals/physician-gls/PDF/infections.pdf. Accessed 8 Apr 2010
12. Lipp HP (2011) Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses 54:32-38. doi:10.1111/j.1439-0507.2010.01984. x
13. Farowski F, Vehreschild J, Cornely OA (2007) Posaconazole: a next-generation triazole antifungal. Future Microbiol 2(3):231-243. doi:10.2217/17460913.2.3.231 (Pubitemid 47180920)
14. Rodriguez MM, Pastor FJ, Calvo E, Salas V, Sutton DA, Guarro J (2009) Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother 53(12):5022-5025. doi:10.1128/AAC.01026-09
15. Kishel JJ, Sivik J (2008) Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 14(4):189-193. doi:10.1177/1078155208094123
16. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H (2007) Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versushost disease. Pharmacotherapy 27(12):1627-1636. doi:10.1592/ phco.27.12.1627 (Pubitemid 350234311)
17. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA (2008) Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28(10):1223-1232
18. Jang SH, Colangelo PM, Gobburu JV (2010) Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 88(1):115-119. doi:10.1038/clpt.2010.64
19. Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, Beresford E, Komjathy S (2009) Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 53(11):4749-4752. doi:10.1128/AAC.00889-09
20. Kohl V, Muller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Ruping MJ (2010) Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 54(1):207-212. doi:10.1128/AAC. 01027-09
21. AbuTarif MA, Krishna G, Statkevich P (2010) Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin 26(2):397-405. doi:10.1185/ 03007990903485056
22. Muller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M (2006) HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 49[Suppl 1]:17-22. doi:10.1111/j.1439-0507.2006.01297.x (Pubitemid 44370097)
23. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79 (3):241-257. doi:10.1016/j.cmpb.2005.04.005 (Pubitemid 41196689)
24. Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard JP, Bougnoux ME, Lecuit M, Jullien V, Lortholary O (2009) Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 53(12):5224-5229. doi:10.1128/AAC.00939-09
25. Thompson GR 3rd, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS 2nd (2009) Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 53 (5):2223-2224. doi:10.1128/AAC.00240- 09
26. Neubauer WC, Engelhardt M, Konig A, Hieke S, Jung M, Bertz H, Kummerer K (2010) Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother 54(9):4029-4032. doi:10.1128/AAC.00150-10
27. Cornely OA, Helfgott D, Krishna G, Carmelitano P, Martinho M, McCarthy M (2010) Pharmacokinetics of different dosing strategies of oral posaconazole, poster A1-042. In: Interscience Conf Antimicrobial Agents and Chemotherapy. Boston
28. Krishna G, Moton A, Ma L, Medlock MM, McLeod J (2009) Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Ch 53(3):958-966. doi:10.1128/Aac. 01034-08
29. AbuTarif MA, Krishna G, Statkevich P (2010) Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin 26(2):397-405. doi:10.1185/ 03007990903485056
30. Shields RK, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Massih RCA, Pilewski JM, Crespo M, Toyoda Y, Bhama JK, Bermudez C, Nguyen MH (2011) Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Ch 55(3):1308-1311. doi:10.1128/Aac.01325-10
31. Alffenaar JWC, van Assen S, van der Werf TS, Kosterink JGW, Uges DRA (2009) Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis 48(6):839-839. doi:10.1086/ 597110
32. Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, Rüping MJGT, Müller C (2010) Intracellular concentrations of posaconazole in different compartments of the peripheral blood. Antimicrob Agents Chemother 54:2928-2931
33. Cornely OA, Helfgott D, Krishna G, Ma L, Carmelitano P, Martinho M, McCarthy M (2010) Pharmacokinetics of different dosing strategies of oral posaconazole, poster 1237). ICAAC, Boston